Answers are grounded in this paper and cite their sources.
The FOLFOXIRI regimen improves RR, PFS, and OS compared with FOLFIRI, with an increased, but manageable, toxicity in patients with metastatic colorectal cancer with favorable prognostic characteristics. Further studies of FOLFOXIRI in combination with targeted agents and in the neoadjuvant setting are warranted.
No takes yet. Share an insight, caveat, or question.
Falcone et al. (2007) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: